288 related articles for article (PubMed ID: 31729943)
1. Anti-VEGF/VEGFR2 Monoclonal Antibodies and their Combinations with PD-1/PD-L1 Inhibitors in Clinic.
Gao F; Yang C
Curr Cancer Drug Targets; 2020; 20(1):3-18. PubMed ID: 31729943
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
Hsu JY; Wakelee HA
BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
[TBL] [Abstract][Full Text] [Related]
3. Targeting CXCR4-dependent immunosuppressive Ly6C
Jung K; Heishi T; Incio J; Huang Y; Beech EY; Pinter M; Ho WW; Kawaguchi K; Rahbari NN; Chung E; Kim JK; Clark JW; Willett CG; Yun SH; Luster AD; Padera TP; Jain RK; Fukumura D
Proc Natl Acad Sci U S A; 2017 Sep; 114(39):10455-10460. PubMed ID: 28900008
[TBL] [Abstract][Full Text] [Related]
4. The effect of bevacizumab on human malignant melanoma cells with functional VEGF/VEGFR2 autocrine and intracrine signaling loops.
Adamcic U; Skowronski K; Peters C; Morrison J; Coomber BL
Neoplasia; 2012 Jul; 14(7):612-23. PubMed ID: 22904678
[TBL] [Abstract][Full Text] [Related]
5. Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth.
Hamerlik P; Lathia JD; Rasmussen R; Wu Q; Bartkova J; Lee M; Moudry P; Bartek J; Fischer W; Lukas J; Rich JN; Bartek J
J Exp Med; 2012 Mar; 209(3):507-20. PubMed ID: 22393126
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts.
Roland CL; Dineen SP; Lynn KD; Sullivan LA; Dellinger MT; Sadegh L; Sullivan JP; Shames DS; Brekken RA
Mol Cancer Ther; 2009 Jul; 8(7):1761-71. PubMed ID: 19567820
[TBL] [Abstract][Full Text] [Related]
7. A functional bioassay to determine the activity of anti-VEGF antibody therapy in blood of patients with cancer.
Wentink MQ; Broxterman HJ; Lam SW; Boven E; Walraven M; Griffioen AW; Pili R; van der Vliet HJ; de Gruijl TD; Verheul HM
Br J Cancer; 2016 Oct; 115(8):940-948. PubMed ID: 27575850
[TBL] [Abstract][Full Text] [Related]
8. VEGF-Independent Angiogenic Factors: Beyond VEGF/VEGFR2 Signaling.
Eguchi R; Kawabe JI; Wakabayashi I
J Vasc Res; 2022; 59(2):78-89. PubMed ID: 35152220
[TBL] [Abstract][Full Text] [Related]
9. Tumor stromal architecture can define the intrinsic tumor response to VEGF-targeted therapy.
Smith NR; Baker D; Farren M; Pommier A; Swann R; Wang X; Mistry S; McDaid K; Kendrew J; Womack C; Wedge SR; Barry ST
Clin Cancer Res; 2013 Dec; 19(24):6943-56. PubMed ID: 24030704
[TBL] [Abstract][Full Text] [Related]
10. Combinations of Bevacizumab With Cancer Immunotherapy.
Chen DS; Hurwitz H
Cancer J; 2018; 24(4):193-204. PubMed ID: 30119083
[TBL] [Abstract][Full Text] [Related]
11. Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation.
Allen E; Jabouille A; Rivera LB; Lodewijckx I; Missiaen R; Steri V; Feyen K; Tawney J; Hanahan D; Michael IP; Bergers G
Sci Transl Med; 2017 Apr; 9(385):. PubMed ID: 28404866
[TBL] [Abstract][Full Text] [Related]
12. Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated - NIVACOR trial (GOIRC-03-2018).
Damato A; Iachetta F; Antonuzzo L; Nasti G; Bergamo F; Bordonaro R; Maiello E; Zaniboni A; Tonini G; Romagnani A; Berselli A; Normanno N; Pinto C
BMC Cancer; 2020 Aug; 20(1):822. PubMed ID: 32867715
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo.
Yasuda S; Sho M; Yamato I; Yoshiji H; Wakatsuki K; Nishiwada S; Yagita H; Nakajima Y
Clin Exp Immunol; 2013 Jun; 172(3):500-6. PubMed ID: 23600839
[TBL] [Abstract][Full Text] [Related]
14. The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials.
Saeed A; Park R; Sun W
J Hematol Oncol; 2021 Jan; 14(1):13. PubMed ID: 33436042
[TBL] [Abstract][Full Text] [Related]
15. An innovative antibody fusion protein targeting PD-L1, VEGF and TGF-β with enhanced antitumor efficacies.
Fan W; Chen Y; Zhou Z; Duan W; Yang C; Sheng S; Wang Y; Wei X; Liu Y; Huang Y
Int Immunopharmacol; 2024 Mar; 130():111698. PubMed ID: 38377856
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic implication of vascular endothelial growth factor receptor-1 (VEGFR-1) targeting in cancer cells and tumor microenvironment by competitive and non-competitive inhibitors.
Lacal PM; Graziani G
Pharmacol Res; 2018 Oct; 136():97-107. PubMed ID: 30170190
[TBL] [Abstract][Full Text] [Related]
17. Development of humanized rabbit monoclonal antibodies against vascular endothelial growth factor receptor 2 with potential antitumor effects.
Yu Y; Lee P; Ke Y; Zhang Y; Chen J; Dai J; Li M; Zhu W; Yu GL
Biochem Biophys Res Commun; 2013 Jul; 436(3):543-50. PubMed ID: 23770369
[TBL] [Abstract][Full Text] [Related]
18. Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models.
Li Y; Amaladas N; O'Mahony M; Manro JR; Inigo I; Li Q; Rasmussen ER; Brahmachary M; Doman TN; Hall G; Kalos M; Novosiadly R; Puig O; Pytowski B; Schaer DA
PLoS One; 2022; 17(7):e0268244. PubMed ID: 35849586
[TBL] [Abstract][Full Text] [Related]
19. VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance.
Michaelsen SR; Staberg M; Pedersen H; Jensen KE; Majewski W; Broholm H; Nedergaard MK; Meulengracht C; Urup T; Villingshøj M; Lukacova S; Skjøth-Rasmussen J; Brennum J; Kjær A; Lassen U; Stockhausen MT; Poulsen HS; Hamerlik P
Neuro Oncol; 2018 Oct; 20(11):1462-1474. PubMed ID: 29939339
[TBL] [Abstract][Full Text] [Related]
20. Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8
Tada Y; Togashi Y; Kotani D; Kuwata T; Sato E; Kawazoe A; Doi T; Wada H; Nishikawa H; Shitara K
J Immunother Cancer; 2018 Oct; 6(1):106. PubMed ID: 30314524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
